The fastest-growing and largest of the 20 sized Pharmaceuticals markets in Brazil, 2023 to 2033, with active clinical trials.
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Biosimilars | $923 Mn | $9.2 Bn | 25.9% | 12 |
| 2 | Cell Based Immunotherapy | $415 Mn | $3.6 Bn | 24% | 553 |
| 3 | Cannabidiol (CBD) | $551 Mn | $2.8 Bn | 17.8% | 10 |
| 4 | Cannabis | $848 Mn | $3.3 Bn | 14.5% | 9 |
| 5 | Atopic Dermatitis Drugs | $281 Mn | $970 Mn | 13.2% | 11 |
| 6 | Oncology/Cancer Drugs | $4.4 Bn | $10.9 Bn | 9.4% | 666 |
| 7 | Anti-Aging | $2.2 Bn | $5.3 Bn | 9.1% | 36 |
| 8 | Diabetes Management | $2 Bn | $4.2 Bn | 8.1% | 65 |
| 9 | Alzheimer Drugs | $125 Mn | $265 Mn | 7.8% | 19 |
| 10 | Contraceptives Drugs | $630 Mn | $1.3 Bn | 7.8% | 1 |
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Oncology/Cancer Drugs | $4.4 Bn | $10.9 Bn | 9.4% | 666 |
| 2 | Anti-Aging | $2.2 Bn | $5.3 Bn | 9.1% | 36 |
| 3 | Diabetes Management | $2 Bn | $4.2 Bn | 8.1% | 65 |
| 4 | Gastrointestinal Drugs | $1.4 Bn | $2.3 Bn | 5.6% | 178 |
| 5 | Asthma & COPD Drugs | $1.2 Bn | $2 Bn | 5% | 34 |
| 6 | Biosimilars | $923 Mn | $9.2 Bn | 25.9% | 12 |
| 7 | Cannabis | $848 Mn | $3.3 Bn | 14.5% | 9 |
| 8 | HIV Drugs | $750 Mn | $1.4 Bn | 6.8% | 33 |
| 9 | Contraceptives Drugs | $630 Mn | $1.3 Bn | 7.8% | 1 |
| 10 | Cancer Supportive Care Drugs | $620 Mn | $1.1 Bn | 5.7% | 118 |
2033 values are projected from the 2023 size and the CAGR. Each market name opens its report. Active trials: recruiting, about to start or running.
Biosimilars grows fastest, at 25.9% a year from 2023 to 2033, ahead of Cell Based Immunotherapy (24%).
Oncology/Cancer Drugs is the largest, worth about $4.4 Bn in 2023 and $10.9 Bn by 2033 (projected).
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide.